34133-58-9

Basic information

• Product Name: 2,4-DIAMINO-PHENOL
• Synonyms: 2,4-DIAMINO-PHENOL;2,4-Dicyanophenol;4-Hydroxyisophthalonitrile;1,3-Benzenedicarbonitrile,4-hydroxy-;FeBuxostat Impurity 35
• CAS NO: 34133-58-9
• Molecular Formula: C₈H₄N₂O
• Molecular Weight: 124.14052
• Mol File: 34133-58-9.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 319℃
• Flash Point: 150℃
• Appearance: /
• Density: 1.34
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.614
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 5.04±0.18(Predicted)
• CAS DataBase Reference: 2,4-DIAMINO-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINO-PHENOL(34133-58-9)
• EPA Substance Registry System: 2,4-DIAMINO-PHENOL(34133-58-9)

Safety Data

• Hazardous Substances Data: 34133-58-9(Hazardous Substances Data)

Usage

Uses

4-Hydroxy-1,3-benzenedicarbonitrile is used in the preparation of febuxostat (F229000), a non-purine xanthine oxidase inhibitor used as a treatment for hyperuricaemia and chronic gout.

InChI:InChI=1/C8H4N2O/c9-4-6-1-2-8(11)7(3-6)5-10/h1-3,11H

Upstream product

• 2976-30-9 1-methanesulfonyl-4-nitrobenzene 
• 151-50-8 potassium cyanide 
• 4387-30-8 4-chloro-1,3-benzenedicarbonitrile 
• 52054-41-8 4-nitroisophthalonitrile 
• 62-53-3 aniline 
• 67-56-1 methanol 
• 619-72-7 4-nitrobenzonitrile 
• 615-58-7 2,4-dibromophenol 
• 23731-06-8 5-(chloromethyl)salicylaldehyde 
• 3328-70-9 5-formyl-2-hydroxybenzaldehyde 
• 90-02-8 salicylaldehyde 
• 22433-92-7 2,4-dicyano-1-methoxybenzene 
• 36914-79-1 acetic acid 2,4-dibromophenyl ester 
• 1885-29-6 anthranilic acid nitrile 

Downstream Products

• 34633-30-2 5-bromo-4-hydroxyisophthalonitrile 
• 34633-31-3 4-hydroxy-5-iodoisophthalonitrile 
• 37142-39-5 4-(2-bromoethoxy)benzonitrile 
• 917226-68-7 4-(3-bromopropoxy)isophthalonitrile 
• 51282-86-1 2.4-Dicyanphenoxy-essigsaeure-ethylester 
• 54176-51-1 5-bromo-4-hydroxyisophthalic acid dimethyl ester 
• 1342299-81-3 6-(methoxycarbonyl)chroman-8-carboxylic acid 
• 95088-64-5 3-bromo-2-hydroxy-5-(methoxycarbonyl)benzoic acid 
• 1342299-76-6 C₁₆H₁₃BrO₅ 
• 1342299-77-7 C₁₉H₁₇BrO₅ 
• 1342299-78-8 C₁₈H₁₆O₅ 
• 1342299-79-9 C₂₁H₂₀O₅ 
• 1342299-80-2 C₁₉H₁₆O₅ 
• 1342299-85-7 C₁₈H₁₅BrO₆ 

Relevant articles and documents

The Synthesis and Transition Temperatures of Ester Derivatives of 2-Fluoro-4-hydroxy- and 3-Fluoro-4-hydroxybenzonitriles also Incorporating Aliphatic Ring Systems

The synthesis and liquid-crystal transition temperatures of forty ester derivatives of 2-fluoro-4-hydroxybenzonitrile and 3-fluoro-4-hydroxybenzonitrile are reported.The esters contain the trans-1,4-disubstituted cyclohexane or the 1,4-disubstituted bicyclooctane rings (some contain an additional phenyl ring).Many of the novel F-substituted esters exhibit substantially higher nematic-isotropic transition temperatures than the corresponding unsubstituted esters.The order of clearing points of these laterally substituted esters differing only in the presence of a benzene ring and the above-mentioned rings is established.

Preparation method and use of 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative

The invention belongs to the technical field of medicines, and relates to a preparation method and a use of a 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative. The invention provides the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative represented by general formula I, or a pharmaceutically acceptable salt, an isomer, a polymorph and a medicinal solvate thereof, and further provides an intermediate for preparing the 2-phenyl-1,6-dihydropyrimidine-5-carboxylic acid derivative or the pharmaceutically acceptable salt thereof. The structure of the intermediate is representedby general formula II, III or IV; and in the formulas, R, R and R are as defined in claims and the description.

COMPOUNDS CONTAINING FUSED RINGS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.